Phase 3Active, not recruiting
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (OASIS-4)
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for an Additional up to 3.5 Years in Women With Hormone-receptor Positive Breast Cancer:
- Sponsor
- Bayer (Industry)
- Enrollment
- 474 enrolled
- Conditions
- Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Hot Flashes
- Interventions
- Elinzanetant (BAY3427080); Placebo
- Ages
- adults, older adults
- Registry
- NCT05587296, CTIS2023-508265-33-00, EUCTR2022-000095-18
Full record on ClinicalTrials.gov
From the registry
Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy. VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these hormones from attaching to these receptors are currently used to slow or stop the growth of HR-positive breast cancer. It is already known that women with HR-positive breast cancer benefit from this treatment. However, hot flashes are common medical problems related to this therapy. They negatively affect quality of life of many women and may lead to discontinuation (stopping) of this therapy.…
Primary outcomes
- Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])
- Mean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)
History
Study completion expected
Last registry update
Results first posted
Primary completion
Registered
Started
In the news
ConferenceBusiness Wire (opens Business Wire in a new tab)
Bayer presents post hoc sleep analysis of menopause drug elinzanetant’s two pivotal trials
The OASIS-1 and OASIS-2 subanalysis examined PROMIS questionnaire scores in women with moderate-to-severe vasomotor symptoms; Bayer presented the findings at the Menopause Society’s annual meeting.
